Authors
Loading...
Post hoc analysis reveals no effect of immunogenicity on efficacy or safety of imetelstat in lower-risk myelodysplastic syndromes, suggesting a stable benefit-risk profile.
Lennox et al. (2025) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: